Advancing Bispecifics for Combination Immunotherapy
Mar 02, 2020•43 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
First recorded at the fourth annual IO Combinations 360° conference, this panel moderated by Dr Daniel Chen, IGM Biosciences discusses advancing bispecifics for combination immunotherapy. This discussion covers the following topics: What are the types of bispecifics and what are the limitations?What are the toxicity related side effects?What are teh next steps/levels for bispecifics?What does the future hold for bispecifics? Panelists include: Julie Bailis, PhD, AmgenRajkumar Ganesan, PhD, Janssen Research & DevelopmentDavid Schaer, PhD, Pfizer To learn more about the 5th annual IO Combinations 360° conference please visit www.iocombinations360.com
For the best experience, listen in Metacast app for iOS or Android